148 related articles for article (PubMed ID: 37424349)
21. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
22. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
23. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna GJ; Busaidy NL; Chau NG; Wirth LJ; Barletta JA; Calles A; Haddad RI; Kraft S; Cabanillas ME; Rabinowits G; O'Neill A; Limaye SA; Alexander EK; Moore FD; Misiwkeiwicz K; Thomas T; Nehs M; Marqusee E; Lee SL; Jänne PA; Lorch JH
Clin Cancer Res; 2018 Apr; 24(7):1546-1553. PubMed ID: 29301825
[No Abstract] [Full Text] [Related]
24. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
De Martino D; Yilmaz E; Orlacchio A; Ranieri M; Zhao K; Di Cristofano A
Cancer Lett; 2018 Dec; 439():56-65. PubMed ID: 30243708
[TBL] [Abstract][Full Text] [Related]
25. Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.
Wang J; Tan J; Wu B; Wu R; Han Y; Wang C; Gao Z; Jiang D; Xia X
J Nanobiotechnology; 2023 Oct; 21(1):374. PubMed ID: 37833748
[TBL] [Abstract][Full Text] [Related]
26. Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines.
Nozhat Z; Mohammadi-Yeganeh S; Azizi F; Zarkesh M; Hedayati M
Daru; 2018 Dec; 26(2):93-103. PubMed ID: 30242671
[TBL] [Abstract][Full Text] [Related]
27. Ellagic acid inhibits cell proliferation, migration, and invasion of anaplastic thyroid cancer cells via the Wnt/β-catenin and PI3K/Akt pathways.
Meng X; Cui Z; Shi H; Ma X; Li W; Liu X; Jiang Y
Acta Biochim Pol; 2023 Feb; 70(1):109-115. PubMed ID: 36773307
[TBL] [Abstract][Full Text] [Related]
28. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics.
Wang Q; Sui G; Wu X; Teng D; Zhu L; Guan S; Ran H; Wang Z; Wang H
Acta Biomater; 2020 Jan; 102():367-383. PubMed ID: 31778831
[TBL] [Abstract][Full Text] [Related]
29. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.
Khan SA; Ci B; Xie Y; Gerber DE; Beg MS; Sherman SI; Cabanillas ME; Busaidy NL; Burtness BA; Heilmann AM; Bailey M; Ross JS; Sher DJ; Ali SM
Head Neck; 2019 Jun; 41(6):1928-1934. PubMed ID: 30758123
[TBL] [Abstract][Full Text] [Related]
30. New therapies for anaplastic thyroid cancer.
Agrawal VR; Hreno J; Patil T; Bowles DW
Drugs Today (Barc); 2018 Nov; 54(11):695-704. PubMed ID: 30539168
[TBL] [Abstract][Full Text] [Related]
31. Myricetin Induces Apoptosis of Human Anaplastic Thyroid Cancer Cells
Jo S; Ha TK; Han SH; Kim ME; Jung I; Lee HW; Bae SK; Lee JS
Anticancer Res; 2017 Apr; 37(4):1705-1710. PubMed ID: 28373432
[TBL] [Abstract][Full Text] [Related]
32. A giant mass in the neck of a young men: a case of anaplastic thyroid cancer.
Salazar-Mejía CE; Pérez-Arredondo LA
Pan Afr Med J; 2018; 30():151. PubMed ID: 30374397
[No Abstract] [Full Text] [Related]
33. Molecular Biomarkers of Anaplastic Thyroid Carcinoma.
Bozorg-Ghalati F; Hedayati M
Curr Mol Med; 2017; 17(3):181-188. PubMed ID: 28828971
[TBL] [Abstract][Full Text] [Related]
34. Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas.
Wang C; Zhang Y
Int J Nanomedicine; 2023; 18():6037-6058. PubMed ID: 37904863
[TBL] [Abstract][Full Text] [Related]
35. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract][Full Text] [Related]
36. Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling.
Liao Y; Gao Y; Chang A; Li Z; Wang H; Cao J; Gu W; Tang R
J Cell Mol Med; 2020 Oct; 24(20):12119-12130. PubMed ID: 32935463
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic thyroid cancer.
Ranganath R; Shah MA; Shah AR
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):387-91. PubMed ID: 26313900
[TBL] [Abstract][Full Text] [Related]
38. GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma.
Gao H; Wang W; Li Q
Cancer Biol Ther; 2022 Dec; 23(1):369-377. PubMed ID: 35491899
[TBL] [Abstract][Full Text] [Related]
39. Co-Delivery of
Huang S; Zhang L; Xu M; Li C; Fu H; Huang J; Jin X; Liang S; Wang H
Adv Healthc Mater; 2021 Feb; 10(3):e2001029. PubMed ID: 33326188
[TBL] [Abstract][Full Text] [Related]
40. GAB1 is upregulated to promote anaplastic thyroid cancer cell migration through AKT-MDR1.
Song P; Xu H; He Y; Sun J; Xu Z; Huang P; Ge M; Zhang X; Ke Y; Cheng H
Biochem Biophys Res Commun; 2022 Jun; 607():36-43. PubMed ID: 35366541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
